In a nutshell This study evaluated the effectiveness and safety of bevacizumab (Avastin) plus TAS-102 (Lonsurf; trifluridine-tipiracil) versus TAS-102 alone for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab combined with TAS-102 was effective with manageable side effects in improving the outcomes...
Read More
In a nutshell This study evaluated which sequence of treatment should be given first, local or systemic (whole-body) treatment for patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). The data showed that systemic treatment followed by local treatment was associated with longer survival for patients with NSCLC and BM. Some...
Read More
In a nutshell This study evaluated the safety and effectiveness of selinexor (Xpovio) in combination with carfilzomib (Kyprolis) and dexamethasone (Decadron) (XKd) in patients with relapsed/refractory (r/r) multiple myeloma (MM) that still responded to carfilzomib. The data showed that weekly administered XKd was highly effective and...
Read More
In a nutshell This study compared the effectiveness of chiglitazar (Bilessglu) and sitagliptin (Januvia) on glycemic (blood glucose) variations, insulin resistance, and inflammation levels in patients with type 2 diabetes (T2D). The data showed that chiglitazar treatment was more effective at improving insulin resistance and inflammation compared...
Read More
In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...
Read More
In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy. This study concluded that this was a suitable treatment...
Read More
In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to...
Read More
In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to other lines of treatment....
Read More
In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...
Read More
In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these...
Read More
In a nutshell This study evaluated the long-term outcomes of using gonadotropin-releasing hormone (GnRH) agonist during chemotherapy to preserve ovarian function in premenopausal patients with early-stage breast cancer (BC). The data showed that GnRH agonist use during chemotherapy was safe and effective to preserve ovarian function in these...
Read More
In a nutshell This study investigated the effectiveness and safety of camrelizumab (SHR1210) in combination with XELOX (capecitabine and oxaliplatin) chemotherapy plus bevacizumab (Avastin) or regorafenib (Stivarga) as first-line therapy in patients with metastatic colorectal cancer (mCRC). The data showed that the combination was effective for these...
Read More
